GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Net Current Asset Value

Pear Therapeutics (Pear Therapeutics) Net Current Asset Value : $0.06 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Pear Therapeutics's net current asset value per share for the quarter that ended in Dec. 2022 was $0.06.

The historical rank and industry rank for Pear Therapeutics's Net Current Asset Value or its related term are showing as below:

PEARQ's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.585
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Pear Therapeutics Net Current Asset Value Historical Data

The historical data trend for Pear Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Net Current Asset Value Chart

Pear Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Current Asset Value
-0.50 0.59 0.57 0.06

Pear Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.34 0.41 0.23 0.06

Competitive Comparison of Pear Therapeutics's Net Current Asset Value

For the Health Information Services subindustry, Pear Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pear Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's Price-to-Net-Current-Asset-Value falls into.



Pear Therapeutics Net Current Asset Value Calculation

Pear Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(72.959-64.544-0-0)/140.454
=0.06

Pear Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(72.959-64.544-0-0)/140.454
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pear Therapeutics  (OTCPK:PEARQ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Pear Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pear Therapeutics (Pear Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 State Street, 13th Floor, Boston, MA, USA, 02109
Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.
Executives
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner officer: Chief Product Dev. Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg officer: Chief Commercial Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien officer: General Counsel & Secretary C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey director, officer: President and CEO C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich officer: Chief Medical Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow officer: Chief Accounting Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre officer: CFO, COO, Treas., & Asst. Sec. 65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery officer: Chief People Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks director C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman director 6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc 10 percent owner 195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891

Pear Therapeutics (Pear Therapeutics) Headlines

From GuruFocus

Pear Therapeutics Announces Process Exploring Strategic Alternatives

By Business Wire Business Wire 03-17-2023

Pear Therapeutics to Participate in the BTIG Digital Health Forum

By Business Wire Business Wire 11-10-2022